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Abstract
Objective. The aim of this study was to evaluate
patient-reported burden associated with peripheral
and central neuropathic pain (NeP) by pain severity
and NeP condition.
Design. Six hundred twenty-four subjects with one
of six NeP conditions were recruited during routine
office visits. Subjects consented to retrospective
chart review and completed a one-time question-
naire (including EuroQol-5 dimensions, 12-item
Short-Form Health Survey, Brief Pain Inventory-
Short Form, Medical Outcomes Study Sleep Scale,
Hospital Anxiety and Depression Scale, and demo-
graphic and clinical characteristics). Pain severity
scores were used to stratify subjects by mild, mod-
erate, and severe pain. Summary statistics and fre-
quency distributions were calculated. Differences
by severity level were compared using Kruskal–
Wallis (continuous variables) and chi-square or
Fisher’s exact test (categorical variables). Effect
size was computed with Cohen’s d (mild vs severe).
Results. Subjects’ mean age was 55.5. The majority
(80.8%) had moderate or severe pain. Patient-
reported outcomes (health status, physical and
mental health, pain interference with function,
sleep, anxiety, and depression) were significantly
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worse among subjects with greater pain severity
(all P< 0.0001). Severe pain subjects were nega-
tively impacted by 30% in each outcome com-
pared with mild pain subjects; standardized effect
size was moderate for anxiety (0.59) and large
(>0.95) for all others. The observed burden was
most substantial among chronic low back pain-NeP,
although the pattern of disease burden was similar
across the six NeP conditions.
Conclusions. Subjects across NeP conditions
exhibited high pain levels, which were significantly
associated with poor function, compromised health
status and sleep, and increased anxiety and depres-
sion. Results indicate substantial patient burden
across broad NeP, particularly among subjects with
severe pain.
Key Words. Neuropathic Pain; Pain Assessment;
Health-Related Quality of Life; Health Status; Bur-
den of Illness; Patient-Reported Outcomes
Introduction
Neuropathic pain (NeP), defined as “pain arising as a
direct consequence of a lesion or disease affecting the
somatosensory system,” is a sequela of a diverse set of
diseases and medical conditions and can be classified as
peripheral or central, depending on the origin in the nerv-
ous system [1,2]. Peripheral neuropathic conditions
include painful diabetic peripheral neuropathy (pDPN),
post-herpetic neuralgia, chemotherapy-induced periph-
eral neuropathy, human immunodeficiency virus (HIV)
sensory neuropathy, post-traumatic/post-surgical (PTPS)
NeP, chronic low back pain (CLBP) with NeP, small fiber
neuropathy, and trigeminal neuralgia. Central neuropathic
conditions include spinal cord injury (SCI)-related NeP,
multiple sclerosis-related NeP, and post-stroke NeP [3].
One study estimated that the prevalence of all types of
NeP among adults in the United States ranges from 3%
to 12%, depending on criteria used to determine preva-
lence [4]. Additionally, the prevalence of NeP varies
widely by underlying NeP condition [5,6]. For example,
in the United States, the estimated prevalence of CLBP-
associated NeP is 2,100 per 100,000, whereas the esti-
mated prevalence is 600 per 100,000 for pDPN, 20 per
100,000 for SCI-related NeP, and 15 per 100,000 for
HIV sensory neuropathy [6]. It is generally believed that
the prevalence of NeP will continue to increase due to
the aging of the population and higher survival rates
from conditions that are associated with NeP (such as
cancer, HIV infection, and diabetes) [7].
NeP is chronic, potentially debilitating, and results in an
incremental burden to patients beyond that of the
underlying condition. Much of the research on the
patient burden of NeP has focused on common periph-
eral NeP conditions, such as pDPN, PTPS NeP, and
CLBP-NeP [8–20]. No published studies were identified
that comprehensively assessed the burden of illness
from the patient’s perspective (including pain severity,
health status, function, sleep, anxiety, and depression)
in the United States across a broad range of peripheral
and central NeP conditions. In Europe, studies have
been conducted among broader samples of NeP,
although the extent to which specific NeP conditions
were represented in these studies was not always
reported and more specific measures of disease bur-
den, such as impact on sleep, mood, and function,
were not consistently included [7,21–26]. Physical and
mental health status, based on the 12-item Short-Form
Health Survey (SF-12), in two studies conducted among
broader NeP samples were similar to that observed in
studies of pDPN [11,14,23,24]. Studies of specific NeP
conditions and broader NeP samples alike found greater
patient burden among those with more severe pain
[7,11,14]. A more thorough understanding of the impact
of NeP from the patient’s perspective across a broader
range of NeP conditions would be beneficial and may
contribute to more informed health care decisions.
The objectives of this research, therefore, were to char-
acterize the patient-reported burden associated with
peripheral and central NeP in routine clinical practice in
the United States with respect to sociodemographic
and clinical characteristics, health status, physical and
mental health, pain interference with function, sleep,
anxiety, and depression, and to evaluate any differences
by pain severity and NeP condition.
Methods
Study Design
This cross-sectional, observational study recruited a con-
venience sample of subjects with 1 of 6 NeP conditions
of interest between September 2011 and June 2012
from 33 community-based physician practices across the
United States, including 9 general practitioners (GPs), 7
neurologists, 6 pain specialists, 3 endocrinologists, as
well as 8 other specialists (e.g., orthopedist, infectious
disease specialist, podiatrist, rheumatologist, etc). Given
the objective to observe characteristics of NeP subjects
in routine clinical practice, a brief feasibility survey was
sent to 711 GPs and specialists treating NeP patients.
This survey described the study design and inclusion/
exclusion criteria, and included questions about site char-
acteristics, such as institutional review board (IRB)
requirements, previous research experience, and NeP
patient volume. A total of 210 sites responded and 149
expressed initial interest in participating. Based on
responses to the feasibility survey, 44 sites were priori-
tized for further evaluation to determine their ability to
identify subjects and participate in the study; among eligi-
ble sites, priority was given to those with the highest
number of potential subjects. Selected sites received
training on the protocol, including the study inclusion and
exclusion criteria, prior to study initiation. This study was
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approved by a central IRB, Concordia Clinical Research
(Cedar Knolls, NJ, USA).
Collectively, selected sites were asked to identify eligible
subjects as they presented for routine office visits. Adult
subjects (18 years) diagnosed with 1 of 6 target NeP
conditions at least 6 months ago who also were man-
aged at the physician’s practice for at least 6 months
were eligible for the study. Subjects also were required to
read and understand English, and must have experienced
symptoms due to neuropathy for at least 3 months prior
to the study. Finally, subjects were required to be willing
and able to provide written informed consent, including
consent for site study staff to obtain information from the
subject’s medical chart. Subjects were not eligible for the
study if they had participated in an investigational drug
study 6 months prior; had a serious or unstable medical
or psychological condition that, in the opinion of the phy-
sician, would compromise participation in the study; or
had a concomitant illness unrelated to NeP that may con-
found the assessment of NeP (e.g., fracture, lupus, rheu-
matoid arthritis). Based on site enrollment logs,
approximately 45% of NeP patients who presented for
office visits at study sites during the study enrollment
Table 1 Case definitions of NeP conditions of interest
NeP Condition
Peripheral or
Central NeP N (% of sample) Case Definition
HIV-related peripheral
NeP (HIV-NeP)
Peripheral 103 (16.5) Subjects with HIV and neuropathies including distal sym-
metrical polyneuropathy, inflammatory demyelinating
polyneuropathy, progressive polyradiculopathy, mono-
neuropathy multiplex, autonomic neuropathy, and dif-
fuse infiltrative lymphocytosis syndrome for at least 3
months, confirmed by a neurologist, using established
diagnostic criteria.
Post-trauma or post-
surgical NeP
(PTPS NeP)
Peripheral 100 (16.0) Patients who experience neuropathic pain following a
known injury or medical intervention. Pain symptoms
may be felt at the site of the injury and/or radiate,
usually away from the site in the normal distribution of
the nerve involved. Pain must be present at least 3
months following the injury or intervention with char-
acteristic NeP qualities.
SCI-related NeP
(SCI-NeP)*
Central 103 (16.5) Patients with 1) SCI (complete or incomplete paraplegia
or tetraplegia) of at least 1 year duration with a non-
progressive (chronic) stage of at least 6 months dura-
tion and 2) NeP that started after the SCI and
persisted continuously for at least 3 months or with
remissions and relapses for at least 6 months.
Chronic low back
pain with NeP
(CLBP-NeP)
Peripheral 106 (17.0) Subjects with low back pain persisting for at least 3
months with a confirmed NeP component based upon
results from validated NeP screening tools.
Painful diabetic
peripheral
neuropathy
(pDPN)
Peripheral 112 (17.9) Patients with diabetic distal symmetrical sensory-motor
polyneuropathy (peripheral neuropathy) with painful
symptoms of at least 3 months duration.
Painful peripheral
neuropathy with
small fiber
involvement (SFN)
Peripheral 100 (16.0) Subjects diagnosed with painful peripheral neuropathy
with small fiber involvement based upon history and
physical exam, and either abnormal quantitative sen-
sory testing findings or decrease in small fibers based
on skin biopsy. Patients with small fiber neuropathy of
known cause, including HIV, post-herpetic neuralgia,
pDPN, or other hereditary forms of small fiber involve-
ment should not be considered part of this NeP
subtype.
*Subjects with SCI-related NeP who also have post-surgical pain were eligible to participate and considered to be in the SCI-
NeP group.
HIV5 human immunodeficiency virus; NeP5neuropathic pain; SCI5 spinal cord injury; SFN5 small fiber neuropathy.
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Table 2 Subject characteristics, overall and by NeP severity level
Characteristic
Overall
(N5 624)
Mild
(N5 110)
Moderate
(N5 297)
Severe
(N5 207) P value*
Age, years 0.0293
Mean (SD) 55.5 (13.74) 58.3 (15.10) 55.7 (13.19) 53.6 (13.33)
Range 19–94 19–94 21–87 22–90
Gender, N (%) 0.0222
Male 346 (55.4) 71 (64.5) 169 (56.9) 101 (48.8)
Female 278 (44.6) 39 (35.5) 128 (43.1) 106 (51.2)
Race, N (%) 0.0015
Missing 11 (1.8) 1 (0.9) 6 (2.0) 4 (1.9)
American Indian or
Alaska Native 9 (1.4) 1 (0.9) 3 (1.0) 5 (2.4)
Asian 5 (0.8) 1 (0.9) 2 (0.7) 2 (1.0)
Black or African American 100 (16.0) 13 (11.8) 37 (12.5) 47 (22.7)
Native Hawaiian or other
Pacific Islander 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
White 448 (71.8) 89 (80.9) 230 (77.4) 122 (58.9)
Multiracial 11 (1.8) 2 (1.8) 4 (1.3) 5 (2.4)
Other 40 (6.4) 3 (2.7) 15 (5.1) 22 (10.6)
Ethnicity, N (%) 0.0151
Missing 28 (4.5) 5 (4.5) 10 (3.4) 12 (5.8)
Hispanic 53 (8.5) 5 (4.5) 21 (7.1) 27 (13.0)
Not Hispanic 543 (87.0) 100 (90.9) 266 (89.6) 168 (81.2)
Education level, N (%) <0.0001
Missing 15 (2.4) 2 (1.8) 6 (2.0) 7 (3.4)
Up to high school/GED 238 (38.1) 20 (18.2) 106 (35.7) 106 (51.2)
Beyond high school 371 (59.5) 88 (80.0) 185 (62.3) 94 (45.4)
Employment status, N (%) <0.0001
Missing 12 (1.9) 4 (3.6) 3 (1.0) 5 (2.4)
Employed for pay 118 (18.9) 30 (27.3) 64 (21.5) 24 (11.6)
Disabled 294 (47.1) 27 (24.5) 131 (44.1) 129 (62.3)
Retired 147 (23.6) 40 (36.4) 74 (24.9) 30 (14.5)
Unemployed 36 (5.8) 6 (5.5) 16 (5.4) 14 (6.8)
Other 17 (2.7) 3 (2.7) 9 (3.0) 5 (2.4)
Time since first NeP symptoms, months 0.0330
Mean (SD) 113.9 (98.32) 93.7 (78.32) 115.4 (102.36) 121.5 (101.52)
Range 0–725 6–393 0–725 5–603
Time since NeP diagnosis, months 0.0059
Mean (SD) 93.9 (81.82) 75.9 (70.29) 94.8 (81.20) 101.7 (86.64)
Range 6–592 6–393 6–534 6–592
BPI-SF Pain Severity Index N/A
N 614 110 297 207
Mean (SD) 5.5 (2.21) 2.0 (1.09) 5.2 (0.80) 7.7 (1.05)
Range 0–10 0–3 4–6 7–10
Number of comorbid conditions† <0.0001
Mean (SD) 3.2 (2.12) 2.5 (1.66) 3.0 (2.07) 3.8 (2.23)
Range 1–11 1–11 1–9 1–9
Note: Scores on the BPI Pain Severity Index were used to classify average pain severity. Ten subjects did not respond to all
required items needed to calculate a BPI average pain severity score and thus were not included in any analysis by pain severity
category (“missing”).
*P values are from the Kruskal–Wallis test for continuous variables; chi-square test for number of comorbid conditions; and Fish-
er’s exact test for the remaining categorical variables; mild vs moderate vs severe.
†Among subjects with at least one comorbid condition.
BPI-SF5Brief Pain Inventory-Short Form; GED5General Education Development; NeP5neuropathic pain; N/A5 not applica-
ble; SD5 ; standard deviation.
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period were formally screened for enrollment; patients
known by the sites to be ineligible (e.g., who did not
have one of the NeP types of interest) were not for-
mally screened. A total of 624 subjects with NeP
were enrolled in the study from 637 who were for-
mally screened. Data are not available for the 13
potential subjects who failed screening.
Data Collection
Subjects were asked to complete a self-administered
one-time questionnaire. The questionnaire assessed
demographics and clinical characteristics and included
the following validated measures: the Brief Pain
Inventory-Short Form (BPI-SF) [27], the 12-item Short-
Form Health Survey, version 2, 1-week recall (SF-12v2)
[28], the EuroQol 5-dimensions (EQ-5D) [29], the Medical
Outcomes Study Sleep Scale (MOS-SS) [30], and the
Hospital Anxiety and Depression Scale (HADS) [31,32].
The BPI-SF includes 4 items measuring pain severity
(worst, least, average, current), whose mean comprises
the Pain Severity Index, and 7 items measuring pain
interference with function, whose mean comprises the
Pain Interference Index [27]. Items were assessed on
11-point numeric rating scales ranging from 0 (no pain)
to 10 (pain as bad as you can imagine).
The SF-12v2 contains 12 items assessing 8 domains of
health status. Composite physical component summary
(PCS) and mental component summary (MCS) scores
were calculated. Scores range from 0 to 100 with
higher scores indicating better health status [28,33].
The EQ-5D is a 5-item general health status and utility mea-
sure [29]. Health state valuation scores range from 20.11
to 1.00with higher scores indicating better health status.
The MOS-SS includes 12 items assessing sleep, with 9
of the 12 items comprising the Sleep Problems Index,
ranging from 0 to 100, with higher scores indicating
worse sleep [30]. For 2 domains (sleep adequacy and
quantity), higher scores indicate better sleep.
The HADS is a 14-item self-reporting tool (7 items each
for anxiety and depression). Scores range from 0 to 21,
with higher scores representing poorer emotional well-
being. Scores of 0 to 7 represent “normal,” 8 to 10
“mild,” 11 to 14 “moderate,” and 15 to 21 “severe” lev-
els of anxiety and depression [31,32].
In addition, the participating physician or site coordinator
conducted a 6-month retrospective review of the sub-
ject’s medical chart to capture clinical characteristics and
NeP-related medications and health care resource use.
Figure 1 The majority of NeP subjects reported moderate or severe pain, regardless of NeP condition*.
*Scores on the BPI-SF Pain Severity Index were used to classify average pain severity. Ten subjects did
not respond to all required items needed to calculate a BPI-SF average pain severity score and thus
were not included in any analysis by pain severity category (“missing”).
†Pain severity levels for the individual NeP conditions have been previously published [15,20,37,38] or are
being submitted for publication.
BPI-SF5Brief Pain Inventory-Short Form; CLBP-NeP5 chronic low back pain with a neuropathic pain
component; HIV-NeP5 human immunodeficiency virus-related peripheral neuropathic pain;
NeP5 neuropathic pain; pDPN5painful diabetic peripheral neuropathy; PTPS-NeP5post-trauma/
post-surgery neuropathic pain; SCI-NeP5 spinal cord injury-related neuropathic pain; SFN5 painful
peripheral neuropathy with small fiber involvement. [Color figure can be viewed in the online issue, which
is available at wileyonlinelibrary.com.]
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Statistical Analyses
Summary statistics, means and standard deviations
(SDs) for continuous variables and frequency distribu-
tions for categorical variables were used to describe the
sample. Summary statistics are presented for all avail-
able data, and data were consistently available for more
than 97.0% of the sample. BPI-SF Pain Severity Index
scores were used to classify pain severity as mild (0 to
3), moderate (4 to 6), and severe (7 to 10) [34,35]. To
evaluate the association between pain severity levels or
NeP conditions and other patient-reported outcomes,
the Kruskal–Wallis test was used for continuous varia-
bles; as such, while the means and SDs were presented
for continuous variables for each group, the P value pre-
sented was based on the ranks. Chi-square or Fisher’s
exact tests were used to examine the association for
categorical variables. Statistical significance was eval-
uated at the 0.05 level. Standardized effect size for
patient-reported outcomes between mild and severe
subjects was computed with Cohen’s d. For Cohen’s d,
an effect size of 0.2 to 0.3 was considered a “small”
effect, around 0.5 a “medium” effect, and 0.8 and
higher was considered a “large” effect [36]. All analyses
were performed using PC-SAS version 9.1.3 (SAS Insti-
tute, Cary, NC, USA).
Results
Demographic and Clinical Characteristics
The 6 NeP conditions were evenly represented
among the 624 subjects, with not more than 18% of
the total sample coming from any one NeP condition
(Table 1). Table 2 presents the demographic and
clinical characteristics of the sample overall and by
pain severity, unless otherwise noted. The mean (SD)
age was 55.5 (13.7) years and 346 (55.4%) were
male. The majority of the sample was white (71.8%)
and non-Hispanic (87.0%), although all racial and
ethnic groups with the exception of native Hawaiian/
other Pacific Islander were represented. Overall, the
majority (59.4%) of subjects completed education
beyond high school.
Figure 2 NeP subjects reported a variety of comorbid conditions*.
*Scores on the BPI-SF Pain Severity Index were used to classify average pain severity. Ten subjects did
not respond to all required items needed to calculate a BPI-SF average pain severity score and thus
were not included in any analysis by pain severity category. A significant difference was observed across
pain severity levels for depressive symptoms (P< 0.0001), sleep disturbance/insomnia (P50.0037), anxi-
ety (P5 0.0003), headache/migraine (P<0.0001), cognitive dysfunction (P50.0491), restless leg syn-
drome (P50.0001), chronic fatigue syndrome (P50.0019), and fibromyalgia (P50.0008).
BPI-SF5Brief Pain Inventory-Short Form; NeP5 neuropathic pain. [Color figure can be viewed in the
online issue, which is available at wileyonlinelibrary.com.]
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Table 3 Patient-reported pain interference with function, health status, and sleep, overall and by NeP
severity level
Measure
Overall
(N5 624)
Mild
(N5 110)
Moderate
(N5 297)
Severe
(N5 207) P value*
Cohen’s d,
Mild vs
Severe†
BPI-SF pain interference with function‡
Pain Interference Index <0.0001 2.68
Mean (SD) 5.6 (2.51) 2.5 (2.01) 5.4 (1.94) 7.3 (1.69)
Range 0–10 0–8 0–10 1–10
General activity <0.0001 2.83
Mean (SD) 5.6 (2.87) 2.1 (2.13) 5.5 (2.37) 7.6 (1.85)
Range 0–10 0–10 0–10 1–10
Mood <0.0001 2.27
Mean (SD) 5.0 (3.04) 1.8 (2.04) 4.8 (2.65) 7.0 (2.39)
Range 0–10 0–9 0–10 1–10
Walking ability <0.0001 1.97
Mean (SD) 5.8 (3.00) 2.8 (2.76) 5.6 (2.66) 7.5 (2.19)
Range 0–10 0–10 0–10 1–10
Normal work§ <0.0001 2.25
Mean (SD) 6.1 (2.89) 2.8 (2.67) 6.1 (2.47) 7.7 (1.93)
Range 0–10 0–10 0–10 1–10
Relations with other people <0.0001 1.63
Mean (SD) 4.4 (3.11) 1.7 (2.29) 4.2 (2.77) 6.0 (2.85)
Range 0–10 0–9 0–10 1–10
Sleep <0.0001 1.77
Mean (SD) 6.2 (3.15) 3.3 (3.09) 6.0 (2.82) 7.9 (2.36)
Range 0–10 0–10 0–10 1–10
Enjoyment of life <0.0001 1.78
Mean (SD) 5.9 (3.03) 3.0 (2.76) 5.9 (2.67) 7.5 (2.43)
Range 0–10 0–10 0–10 1–10
SF-12v2¶
Physical component summary <0.0001 1.42
Mean (SD) 31.1 (9.55) 40.1 (10.64) 30.1 (8.35) 27.8 (7.49)
Range 8–62 14–62 8–60 13–53
Mental component summary <0.0001 0.96
Mean (SD) 42.5 (12.41) 47.9 (11.95) 44.6 (11.68) 36.7 (11.49)
Range 15–74 18–73 16–74 15–68
Physical functioning <0.0001 1.11
Mean (SD) 26.4 (29.79) 48.1 (34.64) 24.9 (28.01) 17.3 (23.72)
Range 0–100 0–100 0–100 0–100
Role physical <0.0001 1.19
Mean (SD) 32.0 (26.93) 53.4 (32.43) 30.6 (23.70) 22.8 (21.57)
Range 0–100 0–100 0–100 0–100
Bodily pain <0.0001 2.14
Mean (SD) 34.6 (27.42) 65.9 (25.95) 34.1 (22.48) 18.8 (19.74)
Range 0–100 0–100 0–100 0–100
General health <0.0001 1.11
Mean (SD) 43.8 (26.62) 60.2 (22.99) 44.7 (26.15) 33.7 (24.53)
Range 0–100 0–100 0–100 0–100
Vitality <0.0001 0.90
Mean (SD) 33.8 (26.42) 46.6 (26.34) 35.9 (24.91) 23.9 (24.92)
Range 0–100 0–100 0–100 0–100
Social functioning <0.0001 1.17
Mean (SD) 48.5 (31.52) 67.3 (30.43) 52.2 (29.56) 33.7 (28.03)
Range 0–100 0–100 0–100 0–100
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Subjects reported a mean (SD) pain severity score of
5.5 (2.2) overall. Close to half of the subjects (47.6%)
reported moderate pain, while a third (33.2%) had
severe pain. The majority of subjects reported suffering
moderately to very strongly from a burning pain sensa-
tion (76.4%); a similar majority reported suffering moder-
ately to very strongly from a prickling pain sensation
(76.9%) (data not shown). The distribution of pain sever-
ity was similar across NeP conditions (Figure 1).
Overall, the mean (SD) time since NeP diagnosis was
7.8 (6.8) years, with a longer duration of NeP observed
among those with greater pain severity (P5 0.0059). On
average, the time from appearance of NeP symptoms
to diagnosis was 20 months (1.7 years). Approximately
three-fourths of the sample reported being originally
diagnosed by a primary care physician (39.3%), a neu-
rologist (23.9%), or a pain specialist (11.4%) (data not
shown). On average, subjects had approximately 3
comorbidities, with more comorbidities among those
with greater pain severity (P< 0.0001). The most com-
mon comorbidities overall were depressive symptoms
(42.6%), sleep disturbance/insomnia (42.1%), and anxi-
ety (35.1%) (Figure 2). Seventy-four (11.9%) subjects
were not able to walk on their own; 50 of these subjects
were SCI-NeP subjects.
Table 3 Continued
Measure
Overall
(N5 624)
Mild
(N5 110)
Moderate
(N5 297)
Severe
(N5 207) P value*
Cohen’s d,
Mild vs
Severe†
Role emotional <0.0001 1.13
Mean (SD) 54.7 (31.58) 73.5 (30.09) 57.8 (29.83) 40.5 (28.69)
Range 0–100 0–100 0–100 0–100
Mental health <0.0001 0.92
Mean (SD) 54.6 (23.56) 65.2 (22.61) 57.6 (21.82) 44.4 (22.83)
Range 0–100 0–100 0–100 0–100
MOS-SS**
Sleep Problems Index <0.0001 1.28
Mean (SD) 50.5 (20.10) 37.5 (18.31) 48.3 (18.41) 60.7 (18.26)
Range 3–100 3–84 4–96 9–100
Sleep disturbance <0.0001 1.14
Mean (SD) 54.5 (27.44) 38.1 (25.56) 51.8 (25.43) 67.0 (25.48)
Range 0–100 0–100 0–100 0–100
Sleep adequacy <0.0001 0.72
Mean (SD) 39.5 (24.81) 50.3 (24.99) 40.4 (23.53) 32.4 (24.83)
Range 0–100 0–100 0–100 0–100
Sleep somnolence <0.0001 0.60
Mean (SD) 44.6 (24.69) 37.0 (23.94) 42.2 (22.93) 52.1 (25.75)
Range 0–100 0–100 0–100 0–100
Snoring 0.0166 0.31
Mean (SD) 40.2 (34.41) 32.3 (33.76) 41.1 (33.69) 42.9 (35.30)
Range 0–100 0–100 0–100 0–100
Shortness of breath or headache <0.0001 0.86
Mean (SD) 23.0 (29.22) 8.2 (19.21) 21.4 (26.51) 33.2 (33.18)
Range 0–100 0–100 0–100 0–100
Sleep quantity <0.0001 0.56
Mean (SD) 6.1 (1.92) 6.7 (1.74) 6.2 (1.71) 5.6 (2.17)
Range 1–20 3–11 2–12 1–20
Note: Scores on the BPI Pain Severity Index were used to classify average pain severity. Ten subjects did not respond to all required items
needed to calculate a BPI average pain severity score and thuswere not included in any analysis by pain severity category (“missing”).
*P values are from the Kruskal–Wallis test; mild vs moderate vs severe.
†An effect size of 0.2 to 0.3 may be considered a “small” effect, around 0.5 a “medium” effect, and 0.8 and higher may be con-
sidered a “large” effect [36].
‡Lower scores indicate a better subject-reported outcome.
§Includes work inside and outside the home.
¶Higher scores indicate a better subject-reported outcome.
**Higher scores indicate more of the concept being measured. Higher scores for “sleep adequacy” and “sleep quantity” represent
better sleep, whereas higher scores for the other scales indicate poorer sleep. BPI-SF5Brief Pain Inventory-Short Form; MOS-
SS5Medical Outcomes Study Sleep Scale; SD5 ; standard deviation; SF-12v2512-item Short-Form Health Survey, version 2.
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Less than a fifth (18.9%) of the sample overall was
employed for pay; the proportions of subjects who were
disabled (47.1%) or who were retired (23.6%) were higher
than the proportion employed for pay. A minority (12.2%)
of subjects were receiving workers’ compensation (data
not shown). Finally, most subjects reported having some
form of health insurance (93.2%), as well as NeP prescrip-
tion drug coverage (87.3%; data not shown).
Pain Interference with Function
The mean (SD) BPI-SF Pain Interference Index was
5.6 (2.5) overall, indicating moderate interference with
function, and the mean Pain Interference Index score
increased among those with greater pain severity
(P<0.0001) (Table 3). The standardized effect size
(Cohen’s d) for the Pain Interference Index when compar-
ing mild and severe subjects was 2.68. Overall, the pain
interference with function items most impacted (mean
score above 5.0) by NeP were sleep, normal work, enjoy-
ment of life, walking ability, and general activity (Table 3).
A significant difference in mean scores was also observed
across pain severity levels for each of the seven pain inter-
ference with function items (all P< 0.0001). The observed
standardized effect size when comparing mild and severe
subjects for all pain interference with function items was
large, ranging from 1.63 to 2.83 (Table 3).
The mean pain interference scores for each of the NeP
conditions are presented in Figure 3. Mean scores
exhibited a similar pattern across NeP conditions and
were consistently the highest/worst among CLBP-NeP
subjects.
Health Status
The mean (SD) SF-12v2 PCS and MCS scores were
31.1 (9.6) and 42.5 (12.4) overall, respectively. Among
subjects with more severe pain, PCS and MCS scores
were lower/worse (both P< 0.0001); a large standar-
dized effect size was observed for both when compar-
ing mild and severe subjects: 1.42 and 0.96,
respectively (Table 3). Average physical and mental
health status overall and in each of the pain severity
groups were lower/worse than the United States popu-
lation norms (49.7 and 49.5, respectively) [28]. A signifi-
cant difference was observed for each of the eight
domains across pain severity levels (all P< 0.0001), and
those with more severe pain had lower/worse mean
scores on each of the eight domains (Table 3). The
most negatively affected domain was physical function-
ing. When comparing mild and severe subjects, the
observed standardized effect size for each of the eight
SF-12 domains was large ranging from 0.90 to 2.14
(Table 3).
Figure 3 Pain interference with function trends is consistent across NeP conditions*
*Significant differences were observed across NeP conditions for all items (all P<0.0010), except walking
ability (P50.1612) and the Pain Interference Index (all P< 0.0010).
CLBP-NeP5 chronic low back pain with a neuropathic pain component; HIV-NeP5 human immunodefi-
ciency virus-related peripheral neuropathic pain; NeP5 neuropathic pain; pDPN5painful diabetic periph-
eral neuropathy; PTPS-NeP5post-trauma/post-surgery neuropathic pain; SCI-NeP5 spinal cord injury-
related neuropathic pain; SFN5painful peripheral neuropathy with small fiber involvement. [Color figure
can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
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Mean SF-12v2 scores for each NeP condition are pre-
sented in Figure 4. Mean SF-12 scale scores exhibited
a similar pattern across NeP conditions and were gener-
ally lowest/worst among CLBP-NeP subjects.
The mean (SD) EQ-5D health utility was 0.55 (0.23) and
decreased as pain severity increased (P< 0.0001) (Fig-
ure 5). The standardized effect size for the EQ-5D health
utility when comparing mild and severe subjects was
2.03. Average scores overall and for each pain severity
group were lower than the population norm of 0.87 [39].
Sleep
The mean (SD) MOS-SS Sleep Problems Index was
50.5 (20.1) overall, which is markedly higher than the
US population norm of 25.8 [30]. Among subjects with
more severe pain, mean scores were higher/worse
(P<0.0001); a large standardized effect size (1.28) was
observed for the Sleep Problems Index when comparing
mild and severe subjects (Table 3). Those with more
severe pain also had worse mean scores across all
domains (all P< 0.02) (Table 3).
The mean MOS-SS subscale scores for each of the
NeP conditions are presented in Figure 6. Mean scores
exhibited a similar pattern across NeP conditions and
were consistently the worst among CLBP-NeP subjects.
Anxiety and Depression
The majority of subjects have some level of anxiety
(61.9%) and depression (54.3%). The mean (SD) HADS
anxiety and depression scores were 8.8 (3.6) and 8.2
(4.5) overall, respectively; indicating mild levels of anxiety
and depression. Similar levels were seen across each of
the NeP conditions. Among subjects with more severe
pain, mean scores were higher/worse (both P< 0.0001),
and the standardized effect size when comparing mild
and severe subjects was 0.59 for anxiety and 1.02 for
depression (Figure 7).
Discussion
To our knowledge, this is the first study in the United
States to comprehensively evaluate the patient-reported
burden of illness associated with broad NeP, that is,
both peripheral and central NeP. Overall, subjects in this
study reported a substantial degree of impairment; NeP
subjects in the sample experienced substantially worse
health status and sleep than the general US population
norms [30,28,39].
The suboptimal patient-reported outcomes we observed
were consistent with previous studies in NeP samples
[7–12,14,21–26]. For example, in previous studies
assessing health status in NeP, subjects reported similar
Figure 4 Trends across domains of physical and mental health are consistent across NeP conditions*.
*Significant differences were observed across NeP conditions for all domains (all P<0.003).
†Mean summary scores for pDPN have been previously published [15].
CLBP-NeP5 chronic low back pain with a neuropathic pain component; HIV-NeP5 human immunodefi-
ciency virus-related peripheral neuropathic pain; NeP5 neuropathic pain; pDPN5painful diabetic periph-
eral neuropathy; PTPS-NeP5post-trauma/post-surgery neuropathic pain; SCI-NeP5 spinal cord injury-
related neuropathic pain; SFN5painful peripheral neuropathy with small fiber involvement. [Color figure
can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
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Figure 6 Trends across domains of sleep are consistent across NeP conditions*.
*Significant differences were observed across NeP conditions for sleep disturbance, sleep adequacy,
shortness of breath or headache domains (all P< 0.03).
†Mean sleep disturbance for PTPS-NeP has been previously published [20].
‡The sleep adequacy item differs from all others in that higher scores indicate better outcomes on this item.
CLBP-NeP5 chronic low back pain with a neuropathic pain component; HIV-NeP5 human immunodefi-
ciency virus-related peripheral neuropathic pain; NeP5 neuropathic pain; pDPN5painful diabetic periph-
eral neuropathy; PTPS-NeP5post-trauma/post-surgery neuropathic pain; SCI-NeP5 spinal cord injury-
related neuropathic pain; SFN5painful peripheral neuropathy with small fiber involvement. [Color figure
can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
Figure 5 NeP subjects with more severe pain have worse general health status*.
*Scores on the BPI-SF Pain Severity Index were used to classify average pain severity. Ten subjects did not
respond to all required items needed to calculate a BPI-SF average pain severity score and thus were not
included in any analysis by pain severity category. EQ-5D health state utility scored on a 20.11 to 1.00 scale;
population norm (0.87 [39]) is indicated by the dark horizontal bar. A significant difference was observed
across pain severity levels for EQ-5D health state utility (P<0.0001). A large standardized effect size
(Cohen’s d) was observed for the EQ-5D health state utility when comparing mild and severe subjects: 2.03.
BPI-SF5Brief Pain Inventory-Short Form; EQ-5D5EuroQol 5-dimensions; NeP5 neuropathic pain. [Color
figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
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mean health utilities, ranging from 0.44 (using EQ-5D)
[7] to 0.56 (using SF-6D) [24] in broad European NeP
samples and 0.50 (using EQ-5D) [11,12] in a American
pDPN sample. Comparable physical and mental health
status scores measured using the SF-12 PCS and MCS
have also been reported among broad European NeP
samples: PCS ranging from 31.29 [24] to 38.9 [23] and
MCS ranging from 40.2 [24] to 40.8 [23]. NeP subjects
from a broad sample in France reported a higher degree
of sleep impairment (mean MOS-SS Sleep Problems
Index 47.4) compared with subjects in our study [23].
Anxiety and depression scores measured using the
HADS in our study were comparable with scores among
pDPN subjects in Asia, Latin America, and the Middle
East (mean anxiety and depression 8.9 and 7.9, respec-
tively) [10].
Subjects in this study were required to have been diag-
nosed with NeP at least 6 months prior and were
actively seeking care. Despite this, the majority of sub-
jects reported a moderate or severe level of pain, which
is consistent with findings previously reported [7,11,14].
In addition, we observed an association between pain
severity and patient-reported outcomes, including health
status, physical and mental health, pain interference
with function, sleep, and mood; severe pain subjects
were negatively impacted by 30% or more for each of
these measures compared with mild pain subjects. The
observed standardized effect size (Cohen’s d) on these
scales ranged from 0.59 for anxiety to 2.68 for pain
interference with function, and a large effect size
(>0.95) was observed for all scales, except anxiety,
when comparing mild and severe subjects. In addition,
when comparing mild and severe subjects, we observed
a medium or large effect size for all individual domains,
except the snoring domain of the MOS-SS (0.31). We
found subjects with severe pain had the highest levels
of pain interference with function (mean 7.3), consistent
with a broad NeP burden of illness assessment con-
ducted in France, Germany, Italy, the Netherlands,
Spain, and United Kingdom (mean 6.8) [7]. Subjects
with severe pain in our sample also had the worst health
status (mean SF-12v2 PCS and MCS 27.8 and 36.7,
respectively, and mean EQ-5D 0.39); in other studies
assessing health status in NeP, subjects with severe
pain have reported similar mean EQ-5D health utilities:
0.16 (broad NeP sample in Europe) [7], 0.2 (American
pDPN sample) [11], and 0.27–0.36 (pDPN samples in
Asia, Latin America, and Middle East) [10]. Finally, sub-
jects in our sample with severe pain reported marked
sleep problems (mean MOS-SS Sleep Problems Index
60.7), which is consistent with previous studies
[10,11,15].
Figure 7 NeP subjects with more severe pain have more anxiety and depression*.
*Scores on the BPI-SF Pain Severity were used to classify average pain severity. Ten subjects did not
respond to all required items needed to calculate a BPI-SF average pain severity score and thus were
not included in any analysis by pain severity category. HADS anxiety and depression scales scored on a
0–21 scale, where 0–7 is normal, 8–10 is mild, 11–14 is moderate, and 15–21 is severe. Significant dif-
ferences were observed across pain severity levels for the anxiety and depression scales (both
P<0.0001). A medium standardized effect size (Cohen’s d) was observed for the anxiety scale when
comparing mild and severe subjects: 0.59. A large standardized effect size (Cohen’s d) was observed for
the depression scale when comparing mild and severe subjects: 1.02.
BPI-SF5Brief Pain Inventory-Short Form; HADS5Hospital Anxiety and Depression Scale; NeP5 neuropathic
pain. [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
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Based on a variety of patient-reported outcome meas-
ures, the findings of this study suggest that the human-
istic burden of NeP is notable. While it is interesting to
understand which NeP patient(s) experience the great-
est burden, we observed similarities in function, health
status, and sleep across the 6 NeP conditions (Fig-
ures 3, 4, and 6). Our findings were most prominent in
CLBP-NeP subjects, which is an important finding given
the high (up to 55%) prevalence of NeP among individu-
als with CLBP in the US population [6,40,41]. Finally,
across NeP conditions, a consistent driver of humanistic
burden was high pain severity.
Despite most patients taking medications to treat their
NeP, the subjects in our study reported high levels of pain
and other symptoms, including depression, anxiety, and
sleep disturbance. This suggests that the management of
NeP remains a difficult challenge for patients and their
health care providers. These findings also support pub-
lished guidelines [42], where tailored NeP management
strategies are advised to include evaluations of depres-
sion, anxiety, sleep, pain, and interference with function.
Limitations
We wish to acknowledge several limitations, particularly
related to the possibility of incurring selection bias.
Enrolled subjects were actively seeking medical care for
their NeP; subjects had been managed at the study site
for at least 6 months prior to enrollment and were
approached to participate in the study as they pre-
sented for a routine medical appointment. As a result,
the proportion of NeP subjects in our study with moder-
ate or severe pain may be different than among all NeP
patients. For example, active patient management may
lead to symptom improvement. Therefore, while our
sample represents NeP patients in routine clinical prac-
tice, findings may not be generalizable to others with
NeP who are not seeking treatment or do not regularly
visit their physician.
Furthermore, this study did not evaluate patient’s treat-
ment compliance or whether prescribed medications
were always filled. Thus, it is possible that the observed
proportion of subjects with moderate or severe pain is
attributable, in part, to lack of compliance with treatment.
While inclusion criteria required that subjects were diag-
nosed with NeP at least 6 months prior to enrollment,
there is a possibility that a proportion of subjects in the
study were misdiagnosed. On average, subjects had
been diagnosed with NeP more than 7 years prior to
enrollment, with over one-third diagnosed by a neurolo-
gist or pain specialist. Clinical characteristics of the sam-
ple are consistent with NeP, for example, a majority of
subjects reported suffering from burning and prickling
pain sensations, and with previously published research.
Nevertheless, we cannot be sure of the extent of the
impact of misdiagnosis on our results. Finally, subjects
who chose to enroll in the study and complete the ques-
tionnaires may have reported more improved scores with
respect to pain, sleep, function, etc., compared with
patients who did not receive this additional attention from
their health care providers (i.e., Hawthorne effect).
Pain and function were assessed at one time point in
our study, while individuals with NeP may experience
day-to-day fluctuations in pain and function. We report
average results in pain and function across a large sam-
ple of 624 subjects to describe the average impact of
NeP; however, results for each subject may not capture
that subject’s typical experience.
Additionally, the BPI-SF Pain Severity Index was used to
classify subjects as mild, moderate, or severe [43].
These cutoff scores have previously been validated
using a sample of patients with pDPN and may not be
the appropriate cutoff points for other types of NeP.
However, Serlin and colleagues identified similar cutoffs
(mild [1 to 4], moderate [5 to 6], and severe [7 to 10])
for assessing pain severity among cancer patients [44].
The use of generic, rather than disease-specific instru-
ments to evaluate pain and other patient-reported out-
comes, could also be a study limitation [45,46]. Using
these generic measures, it may have been difficult for
subjects to distinguish between NeP and other pain.
However, in previous NeP research, these measures
have been used to demonstrate differences between
groups and across time. Future research among
patients with NeP and controls without NeP could be
useful to better understand the incremental burden of
NeP compared with the underlying condition.
Summary
Subjects across NeP conditions exhibited high pain lev-
els. Pain severity was statistically significantly associated
with poor function, compromised health status and
sleep, and increased anxiety and depression. Of the 6
NeP conditions, the observed burden was most sub-
stantial among CLBP-NeP, although the pattern of NeP
impact was similar regardless of NeP condition. Results
of this cross-sectional study indicate substantial patient
burden across broad NeP, particularly among subjects
with severe pain.
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